On the stock market since 2020, it operates in the world of health and science. It has 26 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 29% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 434% — still a thick cushion, though costs have been eating into it lately.
There is $36.4M in the vault; even if every debt were paid off, $25.2M would remain.
Over the last 12 months, company executives reported 39 buys and 32 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.96. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 3 years, sales fell about 20% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, ELUT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ELUT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (17/100) says the stock isn’t cheap.